Nearly 30 per cent of Canadian adults – 9 million people – were infected during the Omicron variant wave early in 2022, compared with just 10 per cent who had been infected in the previous four waves, according to a new study led by Toronto researchers.
MONTREAL, May 9, 2022 - A new seroprevalence study of blood donors, conducted by Héma-Québec, estimates that more than one in four Quebec adults developed antibodies to COVID-19 due to infection between the start of the year and mid-March.
Montreal, May 3, 2022 – New findings, published in The Lancet Rheumatology, suggest that people with immune-mediated inflammatory diseases (IMIDs) respond well to vaccination and that the COVID-19 vaccines in Canada are highly effective in protecting them against hospitalization from COVID-19. The results of this study are highly pertinent for people living with rheumatoid arthritis, ankylosing spondylitis (a type of arthritis that characteristically affects the spine), psoriasis (a skin condition), and inflammatory bowel disease (IBD) – the four patient populations included in the study, supported by the Government of Canada, through its COVID-19 Immunity Task Force (CITF).
Vancouver, April 6, 2022 - As many jurisdictions in Canada begin to ease public health measures intended to limit serious cases and fatalities caused by COVID-19, new research from the BC Centre on Substance Use (BCCSU) and the University of British Columbia (UBC) suggests many people remain at risk of serious disease. The Government [...]
Government of Canada launches second cycle of national survey to assess the health impacts of the COVID-19 pandemic
Ottawa, Ontario | Public Health Agency of Canada Canada’s response to the COVID-19 pandemic is continually guided by the latest science, evidence and research. To that end, the Government of Canada is actively working with a community of national and international experts to gather evidence on the health impacts of the pandemic, as well [...]
The COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG) are supporting a new study that will work with three First Nations communities to investigate vaccine hesitancy, the immune response to the COVID-19 vaccine and health outcomes after vaccination within those communities. As of November 9, 2021, according to Indigenous Services [...]
The Canadian Partnership for Tomorrow’s Health (CanPath) COVID-19 Antibody Study is expanding. The Government of Canada is investing $1.9 million through Canada’s COVID-19 Immunity Task Force (CITF) to fund an extension of CanPath’s existing study over a longer period of time, allowing for an additional collection of blood samples and questionnaire responses from participants. [...]
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF). Principal investigator Dr. Brian Grunau, Assistant [...]
One in five vaccinated long-term care residents were at risk of COVID because of low antibody levels, supporting need for booster shots
New research from McMaster University, aimed at understanding the immune response to COVID-19 vaccines, found some long-term care residents no longer had high antibody levels months after their second dose, directly supporting government decisions to provide third doses.
McMaster University scientists are conducting research on the long-term illness suffered by some patients after they’ve recovered from COVID-19, which may be caused by immune dysfunction.